Expert NetworkExpert InterviewINCY

Slingshot members are talking to an expert! The topic is:

A Second View: Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo

Executed on:Apr 5, 2022 1:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Mount Sinai
  • Medical Director for Dermatology at Mount Sinai Healthcare System.
  • Manages ~100 patients with hidradenitis supportiva & 50 patients with vitiligo.
  • Active in both basic science research and clinical trials, serving as the PI in numerous trials encompassing clinical areas such as psoriasis, atopic dermatitis, Hidradenitis suppurativa, and vitiligo.

Interview Goal

This conversation will focus on discussing the standard of care and the potential of Ruxolitinib Cream (Opzelura) as part of treatment for non-segmental vitiligo in light of the 52 week data from Phase 3 TRuE-V-program by Incyte.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.